Tables
- TABLE 1
Trial descriptions and meta-analysis results
Study Timing and primary outcome Total patients Average age Males Comorbidities Symptom free by day 14 Hospitalised Drug Control Drug Control CONTAIN (placebo) ≤6 days of symptoms
Resolution of cough, dyspnoea, and fever day 7203 37 46.3% 20.2% overall
5.9% HTN
2.5% diabetes
0.5% CAD57/105 44/98 6/105 3/98 Covis Pharma (placebo) ≤72 h of test
Time to symptom free400 43 44.8% 22% HTN
7.5% diabetes81/197 76/203 3/197 7/203 STOIC (open label) ≤7 days of symptoms
COVID-19 urgent visits139 45 42.4% Median of 1
8.4% CAD
5% diabetes63/70 48/69 2/70 11/69 PRINCIPLE (open label) ≤14 days of symptoms
COVID-19 related hospitalisation or death1719 (concurrent) 64 48.5% 80% (median of 1)
43–46% HTN
20–23% diabetes
15–17% CAD251/781 173/794 72/787 98/799 Analysis Pooled risk ratio Probability any benefit Probability NNT ≤50 Probability NNT ≤20 Random Fixed Random Fixed Random Fixed Random Fixed Symptom free day 14 (I2 30%) 1.29 (1.14–1.47) 1.31 (1.18–1.45) 100% 100% 99.8% 100% 93.1% 98.2% Placebo-controlled (I2 0%) 1.15 (0.95–1.38) 1.15 (0.95–1.38) 92.5% 92.7% 78.1% 78.2% 42.6% 43.4% Open label (I2 11.9%) 1.39 (1.22–1.58) 1.39 (1.23–1.56) 100% 100% 100% 100% 99.3% 99.8% Hospitalisation; overall (I2 49.2%) 0.64 (0.31–1.29) 0.72 (0.55–0.95) 89.3% 99.0% 72.9% 78.2% 26.7% 0.7% Placebo-controlled (I2 54.4%) 0.90 (0.22–3.71) 0.90 (0.35–2.33) 54.7% 57.6% 43.0% 40.1% 21.6% 12.3% Open label (I2 71.3%) 0.44 (0.12–1.70) 0.71 (0.59–0.94) 89.1% 99.8% 81.3% 85.3% 57.6% 0.3% COVID-19: coronavirus disease 2019; HTN: hypertension; CAD: coronary artery disease; NNT: number needed to treat.
Supplementary Materials
Supplementary Material
This one-page PDF can be shared freely online.
Shareable PDF ERJ-02921-2021.Shareable
Vol 59 Issue 5
Table of Contents
Inhaled corticosteroids for outpatients with COVID-19: a meta-analysis
